Drug Profile


Alternative Names: MT-5547; REGN 475; SAR 164877

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Regeneron Pharmaceuticals; sanofi-aventis
  • Developer Mitsubishi Tanabe Pharma Corporation; Regeneron Pharmaceuticals
  • Class Monoclonal antibodies; Non-opioid analgesics
  • Mechanism of Action Nerve growth factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Pain
  • Phase II/III Back pain

Most Recent Events

  • 11 Oct 2017 Regeneron Pharmaceuticals plans a phase III trial for Pain (NCT03304379)
  • 25 Sep 2017 Regeneron Pharmaceuticals plans a phase III trial for Back pain (NCT03285646) (EudraCT2017-001943-12)
  • 17 Aug 2017 Regeneron Pharmaceuticals initiates enrolment in a phase III trial for Pain in USA (SC) (NCT03161093)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top